CASI Pharmaceuticals, Inc. · OTC:CASIF
CASI Pharmaceuticals — BIO International 2019
20 slides from CASI Pharmaceuticals's conference presentation, Jul 14, 2019
Slide 1: Corporate Presentation BIO International 2019
Corporate Presentation BIO International 2019 James E. Goldschmidt, Ph.D. Senior Vice President – Business Development CASI Pharmaceuticals, Inc.
Slide 2: Disclaimer
Disclaimer This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward‐looking statements are subject to
Slide 3: Contents
Contents 1 2 3 4 About Us Our Portfolio Our Team Our Strategy 3
Slide 4: About Us
About Us CASI is a U.S. biopharmaceutical company with an 1 aggressive vision to bring innovative pharmaceutical products to China, the U.S., and throughout the world Our first strategic focus is hematology‐oncology and over time will expand into other attractive therapeutic markets 4
Slide 5: Key Milestones
Key Milestones EVOMELA® (Melphalan Hydrochloride for Injection): China marketing approval November 2018 under new priority review guidelines • Indication: treatment of Multiple Myeloma Established top‐tier 50 person marketing/sales team dedicated for EVOMELA® ZEVALIN®: NMPA CTA approval to con
Slide 6: CASI Pharmaceuticals (NASDAQ: CASI)
CASI Pharmaceuticals (NASDAQ: CASI) US and China Synergy • U.S. NASDAQ‐listed biopharmaceutical company with seamless cross‐border operations in Rockville, Maryland and Beijing, China —90+ employees in U.S. & China; global operations led by senior executive team in the U.S. • Management team with ex
Slide 7: Mission
Mission Build a dynamic, fully integrated biopharmaceutical company with an innovative portfolio to address patients’ unmet medical needs in China, the U.S. and globally through licensing and acquisitions 7
Slide 8: Our Portfolio
Our Portfolio CASI is building an innovative product portfolio initially 2 focusing on hematology and oncology 8
Slide 9: Diversified Portfolio of Approved and Pipeline Products
Diversified Portfolio of Approved and Pipeline Products Greater China Rights Global Rights U.S. FDA ANDAs Licensed From SPPI Licensed From Black Belt: Acquired From Sandoz: CID‐103 • 19 FDA Approved ANDAs Anti‐CD38 Monoclonal Antibody • 4 FDA Pending ANDAs • Potential best‐in‐class Acquired TDF from
Slide 10: EVOMELA Approved in China for Multiple Myeloma
EVOMELA® Approved in China for Multiple Myeloma • Evomela® is the only approved melphalan product for China market • In China, high awareness and anticipation of Evomela® as an innovative, branded new treatment for multiple myeloma • Evomela® is stable and easy to handle for physicians • Evomela® pr
Slide 11: CID-103, a Potential Best-in-Class anti-CD38
CID‐103, a Potential Best‐in‐Class anti‐CD38 CASI Pharmaceuticals In‐Licensed Exclusive Worldwide Rights to Novel Anti‐CD38 Monoclonal Antibody April 17, 2019 CID‐103 is a fully human IgG1 anti‐CD38 monoclonal antibody that recognizes a unique epitope on CD38. It was engineered to have strong ADCC a
Slide 12: CID-103, a Potential Best-in-Class anti-CD38
CID‐103, a Potential Best‐in‐Class anti‐CD38 CASI Pharmaceuticals In‐Licensed Exclusive Worldwide Rights to Novel Anti‐CD38 Monoclonal Antibody April 17, 2019 • CASI has global responsibility for development and commercialization activities • CID‐103 is currently at global IND/IMPD submission stage
Slide 13: GMP Manufacturing Facility in Wuxi, China
GMP Manufacturing Facility in Wuxi, China • Building state‐of‐the‐art GMP manufacturing facility strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China —Currently in design phase, breaking ground on Phase 1 in 2019 • Backing from Wuxi government • Centrally lo
Slide 14: Our Team
Our Team Management team and Board of Directors with decades of 3 combined experience in drug development/commercialization and creating innovative companies 14
Slide 15: Management Team
Management Team Wei‐Wu He, Ph.D. Larry Zhang Chairman and Chief Executive Officer President, CASI China • In 2000, Dr. He established Emerging Technology • Former VP, Novartis, China Partners (ETP), a biomedical focused venture • Former, CEO, Sandoz China fund • Held leadership roles at Bayer Asia P
Slide 16: Board of Directors
Board of Directors WEI‐WU HE, PH.D. CEO, CASI Pharmaceuticals; IDG‐ACCEL China Fund Venture Chairman & CEO Partner; Managing Director ETP Global Fund, L.P.; Chairman, OriGene Technologies, Inc. QUAN ZHOU, PH.D. Founder, Managing Director & General Partner at IDG Capital Compensation Committee Partne
Slide 17: Commercial Momentum & Business Strategy
Commercial Momentum & Business Strategy CASI is entering a commercial phase in China and 4 continues to build momentum for a promising future by expanding our product portfolio Through our partnering efforts, we build mutually beneficial relationships in order to provide patients in China and global
Slide 18: Business Strategy
Business Strategy Significantly Enrich Build State‐of‐the‐Art GMP Pipeline Through Facility Business Development Specialized Commercial Accelerate Registration & CASI Teams for Health Segments Commercialization Produce Complex Generics for Niche Markets 18
Slide 19: CASI's Value Proposition
CASI’s Value Proposition A strategic partner for developing and commercializing innovative products in China, the U.S. and globally • Leverage CASI Pharmaceutical’s expertise and resources to accelerate development and commercialization of innovative products into the China and U.S./global markets •
Slide 20: Recap
Recap • U.S. based company – (NASDAQ: CASI) • Launching first product in China fiscal 2019 • Strong cash runway, with expected revenue in 2019 • Backed by returning committed investors and new investors • Experienced cross‐border management team with deep knowledge of drug development, tech transfer